GlobeNewswire Inc.··Hutchmed (China) LimitedHUTCHMED Advances Cancer Pipeline with Phase III HMPL-760 Trial Launch
HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.
HCMclinical developmentoncology